You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023334032
Dec 202348011
Jan 202493012
Feb 20245206
Mar 202492015
Apr 2024104016
May 2024118010
Jun 202410407
Jul 2024108015
Aug 202470010
Sep 2024134010
Oct 202415808
Nov 2024168011
Dec 202413906
Jan 2025131029
Feb 20254805
Mar 20252010
Apr 20250016
May 2025006
Jun 2025008
Total19030243